Viking Therapeutics, Inc.
VKTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $4,387,649 | $1,755,798 | $722,240 | $355,109 |
| - Cash | $26,676 | $55,516 | $36,632 | $26,371 |
| + Debt | $1,119 | $1,260 | $1,564 | $29 |
| Enterprise Value | $4,362,092 | $1,701,542 | $687,172 | $328,767 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$150,575 | -$100,535 | -$70,064 | -$55,386 |
| % Margin | – | – | – | – |
| Net Income | -$109,963 | -$85,895 | -$68,867 | -$54,990 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.01 | -0.91 | -0.88 | -0.7 |
| % Growth | -11% | -3.4% | -25.7% | – |
| Operating Cash Flow | -$87,790 | -$73,376 | -$48,397 | -$47,586 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$87,790 | -$73,376 | -$48,397 | -$47,586 |